Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?

Pharmaceutical industry leaders want a temporary ban on drugs exports to prevent the NHS being hit by shortages in the event of a no-deal Brexit.

Inquiry hears of massive extra costs, a mountain of red tape, shrinking investment and chemicals ‘disappearing’ from UK market.

The UK government has announced a ban on some drug exports to protect NHS patients' access to medicines.

A major voice in the pharma sector echoes warnings that Brexit risks delaying crucial supplies as winter hits its height.

Another year should give enough time to amend Northern Ireland's medicines supply chain after Brexit, an industry expert said.

Focus on substance rather than Diwali deadline, trade secretary Anne-Marie Trevelyan told.

Bloc plans to bulk-buy key drugs for all 27 countries, potentially leaving Britain ‘behind in the queue’. / “Europe is securing access to key drugs and vaccines as a single region, with huge influence and buying power. As a result of Brexit the UK is now isolated from this system, so our drug supplies could be at risk in the future,” said Dr Andrew Hill, an expert on the pharmaceutical trade.